NodThera announces the appointment of Adam Keeney PhD as President and Chief Executive Officer NodThera(“NodThera” or the “Company”) NodThera announces the appointment of Adam Keeney PhD as President and Chief Executive Officer             Dr Keeney joins NodThera with over 20 years of...

NodThera secures £28 million ($40 million) Series A Financing NodThera(“NodThera” or the “Company”) NodThera secures £28 million ($40 million) Series A Financing NodThera discovers and develops next generation NLRP3 inflammasome inhibitors for the treatment...